REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Location: United States, California, Redwood City
Employees: 51-200
Total raised: $100M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 26.11.2025 | Foresite C... | foresiteca... |
| - | The Column... | thecolumng... |
| - | Illinois V... | illinoisve... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2019 | - | $100M | - |
Mentions in press and media 10
| Date | Title | Description |
| 16.10.2025 | Stocks close higher as bank credit worries, China trade tensions ease | The Dow Jones Industrial Average rose Friday as traders digested the U.S.′ softening tone on its trade talks with China and tried to move past credit concerns that sparked a big sell-off in regional banks Thursday. The Dow finished 238.37 p... |
| 11.09.2025 | Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene and more | - |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 08.05.2023 | Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress | /EIN News/ -- First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and c... |
| 16.09.2022 | Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs | Martin Stahl will start as LifeMine Therapeutics' chief scientific officer on October 4. Martin Stahl This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now After 25 years at the phar... |
| 24.11.2021 | Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference | REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addic... |
| 11.11.2021 | Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress - Form 8-K | Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data... |
| 11.08.2021 | Revolution Medicines : Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic (Form 8-K) | Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study Support Deprioritizing Certain Approaches ... |
| 10.07.2019 | Revolution Medicines snags $100M to attack RAS-mutated cancers | Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable... |
| 20.12.2016 | Revolution Medicines Raises $25M in Series A Extension Financing | Revolution Medicines, Inc., a Redwood City, Calif.-based company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, raised $25m in a Series A extension financing. The Column Group joined founding investor Th... |